Get your free ETF data sample from our comprehensive offerings. Start your free trial→

Help us improve your experience. Please confirm your investor type:

Global ETF Survey 2026

Access the report

›ETF Issuers›Tidal›PBPH

PBPH

Portfolio Building Block World Pharma and Biotech Index ETF

Passive ETF Equity

Not rated

The PBPH Exchange Traded Fund (ETF) is provided by Tidal. It is built to track an index: BITA Global Pharma and Biotech Select Index. The PBPH ETF provides physical exposure, so by buying it you actually own parts of all the 53 underlying holdings. This share class generates a stream of income by distributing dividends.

Diversification

Data as of 08/31/26

No. of holdings

Effective diversification

18.3

Total weight of top 15 holdings

74.60%

Top 15 Holdings

Data as of 08/31/26

Eli Lilly & Co.

14.74%

Johnson & Johnson

9.60%

AbbVie, Inc.

6.72%

Merck & Co., Inc.

5.42%

Amgen, Inc.

4.92%

Roche Holding AG

4.59%

Novartis AG

4.14%

Gilead Sciences, Inc.

3.99%

AstraZeneca PLC

3.52%

Pfizer Inc.

3.51%

Novo Nordisk A/S

3.23%

Vertex Pharmaceuticals, Inc.

3.02%

Bristol Myers Squibb Co.

2.99%

Sanofi

2.15%

GSK Plc

2.07%

Sector exposures

Data as of 08/31/26

Healthcare

Unavailable

020%40%60%80%100%

Country exposures

Data as of 08/31/26

USA

Switzerland

United Kingdom

Japan

Denmark

France

Germany

Australia

Unavailable

Other

020%40%60%70%

Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:

More fund data
Compare up to 3 funds
More screener filters
Edit screener columns from 100+ metrics
Watchlists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring

Trackinsight Global ETF Survey 2026: ETFs' Next Act: From Access to Selection. Access the report

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

Portfolio Building Block World Pharma and Biotech Index ETF

Essentials

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US